Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 February;55(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 February;55(1):91-102

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 February;55(1):91-102

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after 186Re-HEDP therapy

Zafeirakis A. 1, Zissimopoulos A. 2, Baziotis N. 3, Limouris G. S. 4

1 Department of Nuclear Medicine, Army Hospital of Athens, Athens, Greece; 2 Department of Nuclear Medicine, Demokriteion University of Thrace, Alexandroupolis, Greece; 3 Department of Nuclear Medicine, St. Savvas Anticancer Hospital of Athens, Athens, Greece; 4 Department of Nuclear Medicine, Aretaieion University Hospital, Athens, Greece


PDF


AIM: In this study, a new method has been used to predict pain response to 186Re-HEDP therapy in patients suffering from painful osseous metastases, on the basis of a modified bone scan index and pre-therapy pain scoring.
METHODS: Forty five patients received a total of 73 doses of 186Re-HEDP during a period of pain relapse without extra-osseous disease progression. All patients were under stable regimen of zoledronic acid, far off other therapeutic manipulations. Imaging studies regarding a modified estimation of bone scan index, were applied; the value of the largest bony lesion (called mBSI), provided that it also corresponded to the most prominent site of osseous pain was taken into account, and a new semi-quantitative index called Double Product Value (DPV), equal to pre-therapy pain score times mBSI was entered in the result analyses, to investigate any possible correlations with response endpoints.
RESULTS: Favourable response occurred in 35/47 evaluated therapeutic doses of 186Re-HEDP (74.5%; excellent response in 12 doses, 25.5%). Responders had significantly lower DPV (3.4±2.3 vs. 10.2±6.2, P=0.0029, for non-responders). Patients with pre-therapy DPV4, and also a longer median period of pain relief (respective mean values 5.9 versus 2.1 months, HR 2.82; P=0.0001).
CONCLUSION: DPV, as developed and implemented in this study proved a valuable and reproducible pre-therapy tool for assessing degree and duration of pain response after 186Re-HEDP therapy.

top of page